Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

274.11USD
4:00pm EDT
Change (% chg)

$-1.12 (-0.41%)
Prev Close
$275.23
Open
$275.59
Day's High
$276.71
Day's Low
$272.50
Volume
366,541
Avg. Vol
581,988
52-wk High
$333.24
52-wk Low
$223.03

Latest Key Developments (Source: Significant Developments)

Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion
Monday, 27 Feb 2017 04:03pm EST 

Perrigo Company Plc : Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion . Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion . Perrigo company plc - deal includes up to $650 million in potential milestone payments based upon future global net sales of tysabri in 2018 and 2020 . Perrigo company plc - transaction is valued at a total consideration of up to $2.85 billion, including $2.2 billion in cash . Perrigo company - royalty pharma will acquire all of perrigo's rights to receive tysabri(® )royalty payments from and after january 1, 2017 . Perrigo company - says royalty pharma will acquire all of perrigo's rights to receive tysabri royalty payments from and after january 1, 2017 . Perrigo company plc - perrigo will also assign to royalty pharma certain information and audit rights under perrigo's existing agreement with biogen . Perrigo - royalty pharma to pay additional payments of $250 million if royalties earned on global sales of tysabri meet specified thresholds during 2018 .Perrigo company- royalty pharma to pay additional payments of $400 million if royalties earned on global net sales of tysabri meet specified thresholds in 2020.  Full Article

Forward Pharma enters license agreement with 2 units of Biogen and other parties
Wednesday, 1 Feb 2017 09:15am EST 

Forward Pharma A/S : Approved entry into settlement, license agreement with 2 wholly owned subsidiaries of Biogen Inc and certain other parties .Forward Pharma - entitled to a non-refundable cash fee of us$1.25 billion within five business days of meeting pursuant to terms of license agreement.  Full Article

Biogen Phase III Alzheimer's trial enrollment ahead of expectations
Thursday, 26 Jan 2017 09:13am EST 

Biogen Inc : Biogen CEO says enrolling of patients for phase III aducanumab Alzheimer's trial ahead of company expectations . Biogen CEO says hoping for swift EU approval of Spinraza for spinal muscular atrophy .Biogen CFO says expects Spinraza revenue uptake to be gradual with majority of 2017 sales in U.S..  Full Article

Biogen qtrly adjusted EPS $ 5.04
Thursday, 26 Jan 2017 06:30am EST 

Biogen Inc : Biogen reports 2016 revenues of $11.4 billion . . Spinraza ( tm ) approved and launched in us for spinal muscular atrophy . Qtrly earnings per share $ 2.99 . Qtrly adjusted earnings per share $ 5.04 . Q4 revenue $2,872 million versus $2,839 million last year . Fy 2017 revenue is expected to be approximately $11.1 to $11.4 billion . 2017 revenue is expected to be approximately $11.1 billion to $11.4 billion . 2017 gaap diluted eps is expected to be between $18.00 and $18.80 . For fy 2017 non-gaap diluted eps is expected to be between $20.45 and $21.25 . Fy2017 earnings per share view $21.02, revenue view $12.08 billion -- Thomson Reuters I/B/E/S . Q4 earnings per share view $4.96, revenue view $2.94 billion -- Thomson Reuters I/B/E/S . Biogen inc- q4 tecfidera revenue of $1,002.0 million versus $992.8 million . Biogen inc says board of directors appoints michel vounatsos as chief executive officer . Biogen inc - q4 avonex revenue of $564 million versus $ 637 million . Biogen inc - q4 tysabri revenue of $473.9 million versus. $480.7 million in the same quarter last year .Biogen inc - q4 plegridy revenue of $125 million versus $103 million in the same quarter last year.  Full Article

Ewopharma partners with Biogen to commercialise Benepali and Flixabi
Monday, 23 Jan 2017 08:43am EST 

Biogen Inc : Ewopharma partners with biogen to commercialise benepali® and flixabi® in central eastern europe . Ewopharma Ag- distribution agreement signed between Ewopharma and Biogen to market and sell co's anti-tumor necrosis factor biosimilars .Ewopharma AG -starting in 2017, Ewopharma will bring Benepali and Flixabi to six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania.  Full Article

Biogen spin-off Bioverativ commences when-issued trading of common stock
Thursday, 12 Jan 2017 08:00am EST 

Biogen Inc - : Biogen spin-off Bioverativ commences when-issued trading of common stock . Advised by Nasdaq that common stock for Bioverativ begins trading today, Thursday, January 12, 2017 .Spin-off is expected to be completed on February 1, 2017..  Full Article

Biogen's board approves separation of Bioverativ
Tuesday, 20 Dec 2016 04:01pm EST 

Biogen Inc : Biogen - for every 2 shares of co's common stock held of record on Jan 17 2017, shareholders will receive one share of Bioverativ common stock . Biogen Inc - its board of directors has approved planned spin-off of its hemophilia business, which will be known as Bioverativ Inc .Biogen's board of directors approves separation of Bioverativ and declares special dividend distribution of Bioverativ stock.  Full Article

Biogen presents data from Phase 1b study of investigational Alzheimer's Disease Treatment at 2016 clinical trials on Alzheimer's Disease Meeting
Thursday, 8 Dec 2016 06:16pm EST 

Biogen Inc : Biogen presents data from Phase 1b study of investigational Alzheimer's disease treatment Aducanumab at 2016 clinical trials on Alzheimer's Disease Meeting .Aducanumab data presented at CTAD are consistent with previously reported analyses from this study.  Full Article

Biogen announces additional members of management team of hemophilia spin-off company Bioverativ
Tuesday, 15 Nov 2016 07:30am EST 

Biogen Inc : Biogen Inc - Appoints Rogerio Vivaldi, M.D. EVP and chief global therapeutic operations officer, and John T. Greene, EVP and chief financial officer . Says spin-off of Bioverativ is on track to be completed in early 2017 .Biogen announces additional members of management team of hemophilia spin-off company Bioverativ.  Full Article

Biogen Q3 non-gaap EPS $5.19
Wednesday, 26 Oct 2016 06:59am EDT 

Biogen Inc : Biogen reports record third quarter 2016 revenues of $3.0 billion . Q3 gaap earnings per share $4.71 . Q3 revenue $3.0 billion versus I/B/E/S view $2.91 billion . Q3 earnings per share view $4.97 -- Thomson Reuters I/B/E/S . Biogen inc qtrly tecfidera revenue $1,034 million versus $937 million . Qtrly plegridy revenue $ 128 million versus $ 100 million . Biogen Inc says foreign exchange negatively impacted total revenues by approximately $54 million in Q3 2016 compared with Q3 of 2015 . Biogen inc qtrly avonex revenue $580 million versus $685 million . Qtrly tysabri revenue $ 515 million versus $ 480 million .Biogen inc - discontinued development of amiselimod (Mt-1303).  Full Article

More From Around the Web

Biogen wins ruling in Tecfidera IP case; shares rise

NEW YORK Biogen Inc on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down.